We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Pfizer (PFE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Pfizer (PFE - Free Report) to post quarterly earnings of $0.74 per share in its upcoming report, which indicates a year-over-year decline of 19.6%. Revenues are expected to be $13.82 billion, up 0.8% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Pfizer metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenues- Oncology- Ibrance- Worldwide' will reach $944.40 million. The estimate points to a change of -3.3% from the year-ago quarter.
Analysts expect 'Revenues- Specialty Care- Xeljanz- Worldwide' to come in at $148.62 million. The estimate indicates a change of +16.1% from the prior-year quarter.
Analysts forecast 'Revenues- Specialty Care- Inflectra- Worldwide' to reach $124.19 million. The estimate points to a change of -18.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Primary Care- Eliquis- Worldwide' should arrive at $1.85 billion. The estimate suggests a change of -3.8% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Ibrance- United States' of $635.94 million. The estimate indicates a year-over-year change of -3.5%.
Analysts' assessment points toward 'Revenues- Specialty Care- Xeljanz- Total International' reaching $96.12 million. The estimate points to a change of -11% from the year-ago quarter.
The consensus estimate for 'Revenues- Oncology- Xtandi- United States' stands at $493.13 million. The estimate points to a change of +7.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Specialty Care- Inflectra- United States' should come in at $100.94 million. The estimate points to a change of -2% from the year-ago quarter.
Analysts predict that the 'Revenues- Specialty Care- Inflectra- Total International' will reach $23.25 million. The estimate points to a change of -53.5% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Pfizer CentreOne- United States' will reach $70.92 million. The estimate points to a change of -1.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Pfizer CentreOne- Total International' will likely reach $189.63 million. The estimate suggests a change of +2.5% year over year.
The average prediction of analysts places 'Revenues- Primary Care- Eliquis- Total International' at $655.20 million. The estimate suggests a change of +5% year over year.
Shares of Pfizer have demonstrated returns of -8% over the past month compared to the Zacks S&P 500 composite's +12.2% change. With a Zacks Rank #3 (Hold), PFE is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Ahead of Pfizer (PFE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Wall Street analysts expect Pfizer (PFE - Free Report) to post quarterly earnings of $0.74 per share in its upcoming report, which indicates a year-over-year decline of 19.6%. Revenues are expected to be $13.82 billion, up 0.8% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Pfizer metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenues- Oncology- Ibrance- Worldwide' will reach $944.40 million. The estimate points to a change of -3.3% from the year-ago quarter.
Analysts expect 'Revenues- Specialty Care- Xeljanz- Worldwide' to come in at $148.62 million. The estimate indicates a change of +16.1% from the prior-year quarter.
Analysts forecast 'Revenues- Specialty Care- Inflectra- Worldwide' to reach $124.19 million. The estimate points to a change of -18.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Primary Care- Eliquis- Worldwide' should arrive at $1.85 billion. The estimate suggests a change of -3.8% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Ibrance- United States' of $635.94 million. The estimate indicates a year-over-year change of -3.5%.
Analysts' assessment points toward 'Revenues- Specialty Care- Xeljanz- Total International' reaching $96.12 million. The estimate points to a change of -11% from the year-ago quarter.
The consensus estimate for 'Revenues- Oncology- Xtandi- United States' stands at $493.13 million. The estimate points to a change of +7.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Specialty Care- Inflectra- United States' should come in at $100.94 million. The estimate points to a change of -2% from the year-ago quarter.
Analysts predict that the 'Revenues- Specialty Care- Inflectra- Total International' will reach $23.25 million. The estimate points to a change of -53.5% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Pfizer CentreOne- United States' will reach $70.92 million. The estimate points to a change of -1.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Pfizer CentreOne- Total International' will likely reach $189.63 million. The estimate suggests a change of +2.5% year over year.
The average prediction of analysts places 'Revenues- Primary Care- Eliquis- Total International' at $655.20 million. The estimate suggests a change of +5% year over year.
View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have demonstrated returns of -8% over the past month compared to the Zacks S&P 500 composite's +12.2% change. With a Zacks Rank #3 (Hold), PFE is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .